These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 16571300)
1. [New types of dopaminergic treatment. The Danish Society of Movement Disorders]. Karlsborg M; Regeur L Ugeskr Laeger; 2006 Mar; 168(12):1209. PubMed ID: 16571300 [No Abstract] [Full Text] [Related]
2. [Effective therapy option in the late phase of Parkinson disease: subcutaneous apomorphine]. Krankenpfl J; 2005; 43(7-10):241. PubMed ID: 16515311 [No Abstract] [Full Text] [Related]
3. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease. Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362 [TBL] [Abstract][Full Text] [Related]
4. Preclamol and parkinsonian fluctuations. Pirtosek Z; Merello M; Carlsson A; Stern G Clin Neuropharmacol; 1993 Dec; 16(6):550-4. PubMed ID: 9377590 [TBL] [Abstract][Full Text] [Related]
5. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Stacy M; Galbreath A Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491 [TBL] [Abstract][Full Text] [Related]
7. Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability. Salazar G; Martín J; Fragoso M; Font MA Neurologia; 2017; 32(6):407-410. PubMed ID: 26699210 [No Abstract] [Full Text] [Related]
8. [Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013]. Aschermann Z; Kovács N; Komoly S Ideggyogy Sz; 2013 May; 66(5-6):209-10. PubMed ID: 23909024 [No Abstract] [Full Text] [Related]